IBL-301 inhibited activation of several proliferative pathways including the MAP kinase pathway proteins ERK and p38, PI3K-Akt pathway and JAK/STAT pathway in NSCLC tumor explants. This evidence concerns the gene PIK3CA and neoplasm.